Eris Lifesciences is set to fully acquire its injectable unit, Swiss Parenterals. The deal involves a share swap valued at Rs 423.3 crore. This move aims to enhance operational control and financial integration. Swiss Parenterals, a significant exporter, has shown consistent revenue growth. Eris also reported strong Q2 performance with increased revenue and profit.